Archive for the ‘Pharmaceutical Industry’ Category
“We recently caught up with Hervé Basset, specialist librarian in the pharmaceutical industry and owner of the blog “Science Intelligence“, to talk about the inspiration behind his recent book entitled “From Science 2.0 to Pharma 3.0″, published by Chandos Publishing and available on Amazon.“
Read the full article on
“A monumental shift is happening that will impact the future of healthcare, according to an Ernst & Young report, which outlines a new approach to healthcare delivery, leading to the reinvention of commercial models within the pharmaceutical industry. (…)
The report, Progressions – The third place: Healthcare everywhere examines how several forces, including patent cliffs; reduced R&D productivity, pricing pressures, globalization and demographics have made the industry’s long-standing blockbuster business model increasingly outdated. These factors fueled a transition known as the move from Pharma 1.0, a vertically integrated blockbuster model to Pharma 2.0, which is the current model based on a more diversified market portfolios and a broader focus on bottom-line returns, not just top-line growth. The move to Pharma 3.0 won’t be automatic. (…)
“What we’re talking about at a very high level is a move to new healthcare system that is based on value and not volume,” (…)
Signs exist indicating that pharma companies are moving customer centricity (…)
Pharma 3.0 is also significant because it involves the transition from blockbuster drugs to more personalized medicine for smaller populations…
Read the full article:
Burns, Mia. Pharma moving toward more customer-centric models. MedAdNews-Pharmalive, online on February, 5th 2013. Available from:
For Pharma 3.0 models, read also:
From Science 2.0 to Pharma 3.0
Available at Chandos:
It seems that Open Pharma is really gaining momentum in the industry, even with Big Pharma. Every week sees news showing Open innovation initiatives…
“Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed. This will allow participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites. ”
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank. Drugs.com, 15 November 2012. Available from:
A fair analysis by PhRMA of this recurrent report on Innovation by Booz & Company…
Booz surveyed trends in R&D spending and innovation strategies, looking at whether a company’s fluctuating investments had any long term effects on their brand’s innovation standards.
From the report:
“There is no long-term correlation between the amount of money a company spends on its innovation efforts and its overall financial performance. Instead, what matters is how companies use that money and other resources, as well as the quality of their talent, processes, and decision making.”
In Booz’s report, the list the top 20 spenders on innovation; eight of them are biopharmaceutical companies:
- N°2, Novartis, $9,6 billions
- N°3, Roche
- N°4, Pfizer
- N°7, Merck
- N°12, J&J
- N°13, Sanofi
- N°16, GSK
- N°20: AstraZeneca
That pharmaceutical companies’ investments represent some of the highest R&D spending but still aren’t viewed as highly innovative by other industries…
Part of the discrepancy lies in a public perception problem. Industries that generate a constant stream of new products are hard to compare to pharmaceutical companies who make incremental progress researching a new medicine over the course of several years. A billion dollars invested into gadget technology can create multiple new products; the same amount spent on molecular biology means you might hopefully understand Alzheimer’s disease only slightly better than you did before.
Look through Booz’s report – it’s a worthwhile read – but remember that it’s tough to compare Apples to medicines.
And someone to comment:
“what constitutes innovation? incremental change larger screen on iphone or innovative healthcare?“
Hollon, Kaelan. New Report Ranks World’s Most Innovative Companies. PhRMA, 13/11/12, Available from:
Reported by David Bradley:
“A case study of six leading pharmaceutical companies – Amgen, Elan, Lundbeck, Merck, UCB and Wyeth – by Annabeth Aagaard of the University of Southern Denmark points to how the industry might adapt to ongoing pressures from rising R&D costs, depreciating patent value and public authority desire to cut healthcare costs.
These challenges have increased the focus on shortening development times and the efficiency of Front-End of Innovation (FEI),…
Aagaard found that the six companies employ very similar approaches to idea management in FEI, which might suggest that innovation would be stifled and the competitive edge lost…
A scientists says, “You have to remember, that we (i.e., the pharmaceutical scientists) all go to the same conferences, are more or less educated in the same places and are moving to and between the same companies, so we share a number of similarities and probably think very much alike when it comes to innovation and how to develop a new drug.”
Read the full article at:
Bradley, David. Skunk pharma. ScienceBase, November 8, 2012. Available from:
A national campaign aimed at making Americans more aware of the prevalence of fake online pharmacies has been launched by the FDA.
The FDA (Food and Drug Administration) warned that fraudulent online pharmacies pose a danger to patient health. The Agency says it aims to help consumers make safe purchases.
American consumers find online pharmacies attractive mainly because many are so cheap compared to retail outlets in the USA. Purchasers can sometimes save from 50% to 80% when buying from foreign websites.
The FDA page:
According this very good study by Mike Ratclife
- To date, only 30%, or 30 companies out of the 100 surveyed have Apps in the Apple Apps Store
- The 30 companies with Apps had launched 101 Apps.
- Nearly two thirds have only launched one or two Apps; The largest number of Apps sponsored by any one single company is nine – Merck and Sanofi.
- All are free whether for the iPhone or iPad. The iPhone is the most popular platform accounting for 75% of all Apps, 50% are on the iPad and 25% are on both platforms.
- These Apps are targeted at either consumers (patients), or professionals (providers). Nearly two thirds are aimed at consumers, while one third at professionals.
Read the full study at:
Ratcliffe, Mike. Pharma & Biotech tap into Mobile Apps. CI Strategy, 21 September 2012, Available from: